Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF Phase 1 in Older Adults
NCT02926430Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Solicited Local Adverse Events at Day 365, Number of Participants With Solicited Systemic Adverse Events at Day 365 and 2 more. Started Nov 2016; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02926430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926430.